ResearcherNanjing University of Chinese MedicineNo recent work listed
Xueting Cai
Matched on ORCID iD 0000-0003-2676-9283; OpenAlex author ID A5101927293. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper
Papers 3
- Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. Co-author DOI 10.1016/j.ejphar.2023.175703↗
- Identification of a novel PAK1 inhibitor to treat pancreatic cancer. Co-author DOI 10.1016/j.apsb.2019.11.015↗
- Digitoflavone inhibits IκBα kinase and enhances apoptosis induced by TNFα through downregulation of expression of nuclear factor κB-regulated gene products in … Co-author DOI 10.1371/journal.pone.0077126↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Peng Cao · 3 shared papers, 2013–2023 · strength 0.31
- Paper Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. DOI 10.1016/j.ejphar.2023.175703↗
- Paper Identification of a novel PAK1 inhibitor to treat pancreatic cancer. DOI 10.1016/j.apsb.2019.11.015↗
- Paper Digitoflavone inhibits IκBα kinase and enhances apoptosis induced by TNFα through downregulation of expression of nucle… DOI 10.1371/journal.pone.0077126↗
- Weikang Kong · 1 shared paper, 2023 · strength 0.17
- Wenjing Ji · 1 shared paper, 2023 · strength 0.17
- Yuhan Yang · 1 shared paper, 2020 · strength 0.10
- Jiaqi Wang · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.